1 Point Away From Winning the Gold Medal! DeepMind Combined AI System Solved IMO Geometry Problems in 19 Seconds; Yaosu Technology Completed 100 Million Yuan Angel + Round of Financing, and Continued to Promote AI + Organoid Chips
AI for Science Company News Overview——
* Google DeepMind combined AI system solved IMO geometry problem in 19 seconds, missing gold medal by 1 point
* Xili Technology received US$30 million in Series A financing to promote "oral gene therapy" with AI+RNA
* Cambridge University develops AI model that can predict Alzheimer's disease in advance with an accuracy rate of up to 80%
* Yaosu Technology completed 100 million yuan angel+ round of financing and continued to promote AI+ organoid chips
* Google team uses AI to mine clinical data to improve gene discovery and disease prediction, published in Nature journal
* Huiguan Bio completed tens of millions of yuan in Pre-A round of financing, focusing on advanced cell imaging technology
* AI pharmaceutical company InnoMab received angel+ round financing to deeply integrate proteomics technology platform with drug development
Google DeepMind combined AI system solved IMO geometry problem in 19 seconds, 1 point away from winning the gold medal
The 65th International Mathematical Olympiad (IMO) was held recently. Google DeepMind's combined AI system solved the IMO geometry problem in just 19 seconds, scoring 28 points (out of a total of 42 points), equivalent to the level of a silver medalist. It is reported that this result is only 1 point away from the gold medal standard, and only 58 of the 609 contestants this year won the gold medal.
The DeepMind combined AI system combines AlphaProof, a new breakthrough formal reasoning model, with AlphaGeometry 2, an improved version of the previous system. The AlphaProof system uses reinforcement learning to combine a pre-trained language model with the AlphaZero algorithm; AlphaGeometry 2 is an improved version of AlphaGeometry, whose language model is based on Gemini and trained on an order of magnitude more synthetic data than its predecessor.
Xili Technology received US$30 million in Series A financing to promote "oral gene therapy" with AI+RNA
Recently, ReviR Therapeutics announced the completion of a USD 30 million Series A financing round, led by Longpan Investment, with continued investment from CDH Investments, 5Y Capital, and Yayi Capital, and followed by Jingtai Technology and CMT Research Foundation.
This round of investment will be used to further build ReviR's self-developed AI drug research and development platform VoyageR, and continue to advance the preclinical and clinical development of the existing Huntington's disease (HD) pipeline as well as pipelines related to various neurological diseases including Charcot-Marie-Tooth Disease (CMT) and Amyotrophic Lateral Sclerosis (ALS).
It is reported that ReviR was founded in 2021. It is a biotechnology company that combines AI technology to develop targeted RNA small molecule drugs. It is committed to conducting more effective and safe targeted RNA therapy research through cutting-edge technology and AI drug development platform VoyageR, thereby solving the long-standing unmet clinical needs of tumors and genetic diseases.
Cambridge University develops AI model that can predict Alzheimer's disease in advance with an accuracy rate of up to 80%
Recently, researchers from the University of Cambridge and other institutions in the UK used machine learning algorithms to build an AI prediction model and tested the model using real-world data from multiple clinics in the UK, Singapore, etc. The team said that the model can not only avoid invasive or expensive tests, but also predict Alzheimer's disease earlier.
The test results show that the model has an accuracy rate of 82% in identifying people who will develop Alzheimer's disease within 3 years, and an accuracy rate of 81% in identifying people who will not develop Alzheimer's disease within 3 years.
The related research was published in the journal The Lancet under the title “Robust and interpretable AI-guided marker for early dementia prediction in real-world clinical settings”.
Paper link:
https://www.thelancet.com/journals/eclinm/home
Yaosu Technology completed a billion-yuan angel+ round of financing and continued to promote AI+ organ-on-chip
Recently, biotech startup Xellar Biosystems announced the completion of an angel+ round of financing worth hundreds of millions of RMB, which will help the company further develop its AI+ organ-on-chip technology platform and promote its in-depth application in the field of new drug research and development.
It is reported that Yaosu Technology was established in Boston, USA at the end of 2021. It is the world's first "3D-Wet-AI" biotechnology startup company that integrates organoid chips, high-content three-dimensional cell imaging, computer vision and AI technologies for drug discovery.
In August 2022, Yaosu Technology completed a US$10 million angel round of financing invested by Legend Capital, ZhenFund and Yayi Capital.
Google team uses AI to mine clinical data to improve gene discovery and disease prediction, published in Nature journal
Recently, the genomics team at Google Research has made progress in using high-dimensional clinical data (HDCD) to characterize diseases and biological features. They proposed an unsupervised deep learning model, REGLE, to discover the association between gene variants and HDCD.
The model is computationally efficient, does not require disease labels, and can integrate expert-defined knowledge information. The clinically relevant information it contains exceeds the information captured by existing expert-defined features and can improve gene discovery and disease prediction.
The related research was published in "Nature Genetics" under the title "Unsupervised representation learning on high-dimensional clinical data improves genomic discovery and prediction".
Paper link:
https://www.nature.com/articles/s41588-024-01831-6
Huiguan Bio completed tens of millions of yuan in Pre-A round of financing, focusing on advanced cell imaging technology
Recently, Wuhan Huiguan Biotechnology Co., Ltd., a high-end biomedical imaging technology provider, completed a Pre-A round of financing of tens of millions of yuan, which will be used to enhance the company's R&D capabilities, expand product line layout, develop the market, and optimize the upstream and downstream of the industrial chain.
It is reported that Huiguan Bio was founded in September 2022 and focuses on the development of advanced cell imaging technology. The company uses its independently innovative light field control technology and brain-like AI image algorithm as its core technology, and is committed to providing the market with high-end imaging instruments and services.
AI pharmaceutical company InnoMab receives angel+ round of financing to deeply integrate proteomics technology platform with drug development
Recently, InnoMab Biopharmaceuticals Co., Ltd. completed the angel+ round of financing from Dandelion (Shenzhen) Pharmaceutical Venture Capital. The financing will be used to deeply integrate the proteomics technology platform with drug research and development to create multiple ADC pipelines with best-in-class potential.
Public information shows that InnoMab is a company that uses omics big data to drive targeted drug research and development, as well as the development of new precision medicine decision-making tools.
The company has established a drug development decision-making tool platform based on proteomics technology, PDX/PDO and other highly clinically relevant disease model libraries; it uses high clinical relevance big data and deep biological knowledge obtained by AI computing to promote the high success rate development of self-developed new drug pipelines and IVD products.